ArticleNPJ breast cancer2026
Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06734533 (A New Option for Post-CDK4/6is Resistance Era), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6is.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study (NCT06734533, registered in ClinicalTrials.gov on November 3, 2024) evaluated the efficacy and safety of anlotinib-containing regimens in patients with HR + /HER2- advanced breast cancer who have progressed on prior CDK4/6 inhibitor therapy. From January 2020 to March 2025, 80 patients were included. With a median follow-up of 9.2 months, the median progression-free survival was 6.4 months (95% CI, 5.2-7.1). Age ≥ 60 years and bone metastasis were identified as poor predictors of PFS, whereas prior treatment with CDK4/6 inhibitor for ≥ 6 months was a favorable predictor. The objective response rate and disease control rate were 30.0% (95% CI, 19.6-42.1) and 87.1% (95% CI, 77.3-93.1), respectively. Grade 3-4 adverse events were observed in 10 patients (12.5%), with the most common being neutropenia (3.8%) and aspartate aminotransferase increased (3.8%). Given the retrospective design and potential confounding of this analysis, these findings should be interpreted with caution. Anlotinib-containing regimens showed potential clinical activity in this patient population and warrant further evaluation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.